Background: Preeclampsia, the most common serious complication of pregnancy, is characterized by vasoconstriction, dysfunction of the vascular endothelium, and hypertension. Unidentified genetic factors and impaired nitric oxide (NO)-mediated vasodilation are thought to contribute to the development of the syndrome. Polymorphisms of the endothelial nitric oxide synthase (eNOS) gene affect NO production and have been associated with hypertension and preeclampsia in a Japanese population.
P
reeclampsia is the most common serious complication of pregnancy and has a familial predisposition. Although the exact pathophysiology has not been defined, genetic factors and impairment of nitric oxide (NO)-mediated vasodilation appear to play important roles in the development of this condition. [1] [2] [3] It is unlikely that a single gene causes preeclampsia. Several maternal genetic variations, in conjunction with environmental factors and a paternal component, may predispose to the development of the disease. Several investigations have attempted to establish or refute the role of endothelial nitric oxide synthase (eNOS) as a candidate gene for the development of preeclampsia. 4 -9 Nitric oxide produces vasodilation and inhibition of platelet aggregation. NO production is upregulated during pregnancy, facilitating pregnancy-associated vasodilation. 10 -12 Loss of this normal NO modulation during pregnancy because of a relative or absolute lack of NO may contribute to the development of preeclampsia. Consistent with this suggestion is the association of familial, pregnancy-induced hypertension with a locus in the region of chromosome 7q36, which also encodes the eNOS gene 5 ; however, this association has not consistently been reported. 4, 9 The eNOS gene has a common polymorphism at position 298 (Glu298Asp). The Glu298Asp eNOS polymorphism has been associated with both altered NO production 13 and with vascular disorders including hypertension, 14 myocardial infarction, 15 coronary artery spasm, 16 stroke, 17 and renal disease. 18 Two Japanese studies reported association of the Asp allele with severe preeclampsia 6 or gestational hypertension, with or without proteinuria. 8 This association may not exist in other ethnic groups, as there is a marked difference in NO-mediated vasodilation and distribution of the Asp298 allelic variant of the eNOS gene among different ethnic populations. 19 In addition, findings in severe preeclampsia do not necessar-ily apply to the more common syndrome of mild preeclampsia. We performed a case-control study to evaluate the association of this polymorphism of the eNOS gene with preeclampsia in an American population.
Methods

Subjects
With Institutional Review Board approval and written informed consent from all subjects, we obtained blood samples for genotyping from women delivering at Columbia Presbyterian Medical Center. Women were considered to have preeclampsia if they met the 1996/2000 American College of Obstetricians and Gynecologists criteria for the definition of preeclampsia: systolic blood pressure Ͼ140 mm Hg or diastolic blood pressure Ͼ90 mm Hg, occurring on at least two occasions 6 h apart, with proteinuria Ͼ0.3 g/L in a 24-h specimen, or a proteinuria dipstick reading of 2ϩ on a random urine collection, with no prepregnancy history of essential hypertension or hypertension before 20 weeks gestation. Blood pressures were determined using the automated blood pressure module of a Hewlett-Packard M1176A model 66 (Hewlett-Packard, Andover, MA) with the patient in the supine position. A total of 64 women with preeclampsia were genotyped and compared with 397 healthy normotensive women delivering at term.
DNA Genotyping
Blood samples were obtained and genomic DNA was isolated from peripheral blood. The eNOS polymorphism of interest, Glu298Asp, was detected using a polymerase chain reaction (PCR)-based restriction enzyme analysis. In brief, an exonic fragment was amplified by PCR with a forward primer 5Ј-AAG GCA GGA GAC AGT GGA TGG A-3Ј, and reverse primer 5Ј-CCC AGT CAA TCC CTT TGG TGC TCA-3Ј at the annealing temperature of 60°C. A quantity of 15 L of PCR products was digested overnight at 37°C with 10 units of the restriction enzyme MboI (New England Biolab, Beverly, MA). The digested PCR products were run on 3% agarose gel to check their patterns. Wild-type (894G allele) was uncut, whereas the variant type (894T allele) was cut into 158 and 90 bp. Genotypes were confirmed by direct sequencing.
Statistical Analysis
The genotype frequencies were calculated, and significance of differences in genotype between cases and controls were determined using the 2 or Fisher's exact test, with P Ͻ .05 being the minimal value accepted as statistically significant.
Results
Hispanic and white women were found to have a similar distribution of eNOS genotypes; therefore the data for the two ethnic groups were combined. The controls and women with preeclampsia did not differ in their demographic or clinical characteristics, except for higher systolic and diastolic blood pressure in the preeclamptic group (Table 1 ). There was a higher percentage of nulliparous women in the preeclampsia group versus the control group, consistent with the known tendency for preeclampsia to occur more often in first pregnancies, but this difference in parity distribution did not achieve statistical significance. Genotype frequencies were in Hardy-Weinberg equilibrium (HWE) in the both preeclamptic and control women (observed versus expected, both P Ͼ .05). No difference between the controls and women with preeclampsia was observed in the frequency of eNOS genotypes or alleles (Table 2) .
Discussion
We did not find an association between the Asp298 variant of the eNOS gene and the risk of developing preeclampsia No statistically significant differences between genotypes or alleles (P Ͼ .05).
among Hispanic and white women. The study had approximately an 80% power to detect a 15% difference in Asp allele frequency between the control and preeclamptic groups. This polymorphism was recently reported to be a marker of increased risk for developing severe preeclampsia in a Japanese population; in that cohort study, the Asp allele was present in 28.8% (27.5% heterozygous and 1.3% homozygous) of women with severe preeclampsia versus 14.1% (12.9% heterozygous and 1.2% homozygous) in the control group (P Ͻ .01). 6 Women with mild preeclampsia were not different from the control group (11.4% heterozygous and no homozygous). The same investigators also demonstrated an association among Japanese women between placental abruption and the Asp298 allele (40% heterozygous Glu298Asp in the placental abruption group, versus 13% in control subjects), supporting the hypothesis that the Asp298 variant may cause arteriolar vasoconstriction resulting in placental ischemia and subsequent abruption. 20 Another Japanese study showed that the Asp298 allele was twice as frequent in women with gestational hypertension with or without proteinuria (23% in hypertensive patients v 12% in controls). 8 Our results may differ from those of the Japanese studies 6, 8 for several reasons. There may well be ethnic differences in the phenotypic expression of eNOS polymorphisms, so that one group with the aspartate variant will develop more hypertensive symptoms than another. In addition, there are undoubtedly ethnic (and socioeconomic) differences in the incidence, etiology, and manifestations of gestational hypertension and preeclampsia. Indeed, in one of the Japanese studies there did not appear to be an association of the eNOS polymorphism with mild preeclampsia, 6 but in the other, an association was found. 8 Very recently, Yoshimura et al 21 attempted to replicate their finding of an association of Glu298Asp298 with preeclampsia in a non-Japanese population in a developing country (ie, Bangladesh). They did not find any association of preeclampsia with the eNOS genotype. Their explanation was that the incidence of preeclampsia in a developing country might be so high that it difficult to detect genetic associations of this magnitude. Hakli et al 22 also very recently reported no association of the Asp298 polymorphism with preeclampsia or even a possible protective effect in a Finnish population. This recent data combined with ours suggests that the association is either not present or is not generalizable outside the Japanese population.
Larger studies or studies more specifically targeting genetically defined groups would shed some light on the nature or strength of any association of eNOS genotype and preeclampsia. In particular, the Asp homozygous genotype may warrant some attention. This genotype was very rare (Ͻ1%) in the two Japanese studies, but we found 25 of 461 subjects homozygous for Asp298 (8% of preeclamptic subjects were Asp homozygotes compared with 5% of the controls, but the numbers were not large enough to achieve statistical significance).
Another polymorphism of the eNOS gene, a 27-bp repeat in intron 4, has recently been shown to result in lower concentrations of plasma NO metabolites in a nonpregnant Japanese population. 23 However, there are conflicting reports regarding the association between this variant of the eNOS gene and preeclampsia. 5, 7 The physiological effects of the Glu298Asp eNOS polymorphism have not been clearly defined. An in vitro study demonstrated that preeclamptic women homozygous for the Asp298 polymorphism had 50% of placental eNOS enzyme compared with Glu298 homozygous women, but with increased enzyme activity. 24 There has been one recent in vivo functional study examining the effect of the Glu298Asp polymorphism on NO-mediated vasodilation in early pregnancy. Homozygosity for the Asp298 allele was associated with significantly lower brachial artery flow-mediated dilation, an NO-dependent response, in pregnant women at 12 weeks gestation (10.12% Ϯ 3.45% in Glu298 homozygotes, 9.01% Ϯ 2.96% in heterozygotes, 7.99% Ϯ 1.46% in Asp298 homozygotes, P ϭ .01). 25 This finding indicates that vascular adaptation to pregnancy might be affected by the eNOS genotype. However, the lack of an association with the Asp variant in our study, combined with the failure to find an association in the recent study in Bangladesh 21 and Finland, 22 suggests that this common genetic variant of eNOS is unlikely to be a major factor in the overall incidence of the syndrome. More detailed mechanistic studies evaluating the relationship between the Asp298 variant of the eNOS genotype, eNOS activity, and NO production as well as its impact on blood pressure regulation during pregnancy and preeclampsia are likely to be necessary to better define any relationship between the eNOS gene and the risk of developing preeclampsia.
In conclusion, we did not find an association between the Asp298 eNOS variant and preeclampsia in an American population of white and Hispanic women.
